TNFA Specific Neutra™ Antibody Products

Are you struggling with prolonged timelines in drug discovery, inconsistent neutralization data, or lack of robust tools for TNFA-targeted therapies? Creative Biolabs' TNFA specific neutra™ antibody products overcome these challenges through advanced epitope-specific engineering, enabling precise blockade of TNFA-receptor interactions to streamline preclinical validation and therapeutic development.

Introduction to TNFA

Tumor necrosis factor alpha (TNFA) is a pleiotropic cytokine central to systemic inflammation, immune modulation, and cellular homeostasis. Secreted primarily by activated macrophages and lymphocytes, TNFA exists in soluble (sTNFA) and transmembrane (tmTNFA) forms, both binding to TNF receptors (TNFR1/R2) to activate downstream pathways. Dysregulated TNFA signaling is implicated in autoimmune disorders, chronic inflammation, and cancer, making it a high-priority therapeutic target.

• Basic Information

TNFA is encoded by the TNF gene on chromosome 6p21.3. It functions as a homotrimer, with each monomer containing conserved β-strands critical for receptor engagement. TNFA production is tightly regulated at transcriptional and post-translational levels, involving TACE (ADAM17)-mediated cleavage of tmTNFA to release sTNFA. Its expression is induced by pathogens, stress signals, or cytokines like IL-1 and IFN-γ.

• Structure

The TNFA trimer is structured in a triangle pyramid, with three monomers forming a compact hydrophobic core. Each subunit comprises an N-terminal domain (stabilizing trimer assembly), a receptor-binding domain (RBD), and a C-terminal domain facilitating membrane anchoring in tmTNFA. Structural studies reveal that TNFA binding to TNFR1 induces receptor trimerization, activating canonical NF-κB and MAPK pathways.

• Related Signaling Pathways

-NF-κB Pathway: Drives pro-inflammatory gene expression (e.g., IL-6, COX-2). Persistent activation contributes to autoimmune pathologies.

-MAPK Pathway: Regulates cell differentiation, apoptosis, and cytokine production.

-Apoptosis Pathway: Mediated via caspase-8 activation upon TNFR1 internalization.

These pathways collectively influence immune cell survival, tissue remodeling, and disease progression.

Fig. 1 Overview of TNFA/TNF-α downstream signaling pathway.¹

• Associated Diseases

TNFA hyperactivation is pathogenic in rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, and ankylosing spondylitis. Elevated sTNFA levels correlate with cachexia in cancer and cytokine storms in sepsis. Anti-TNFA therapies have revolutionized treatment for these conditions, underscoring the need for high-specificity neutralizing antibodies.

Clinical Applications of TNFA Neutralizing Antibodies

• Targeted Therapy for Autoimmune Disorders

Anti-TNFA antibodies are approved for RA and Crohn's disease. They reduce synovitis and intestinal inflammation by blocking TNFA-induced leukocyte infiltration and tissue degradation.

• Sepsis Management

In septic shock, excessive TNFA drives multiorgan failure. Neutralizing antibodies mitigate cytokine storms, improving survival in preclinical models by suppressing endothelial activation and coagulation dysregulation.

• Oncology Combination Therapies

TNFA inhibitors enhance checkpoint inhibitor efficacy by remodeling the tumor microenvironment. For example, neutralizing TNFA reduces myeloid-derived suppressor cell (MDSC) infiltration, amplifying anti-PD-1 responses in melanoma models.

• Chronic Inflammatory Diseases

Anti-TNFA agents like etanercept (a TNFR2-Fc fusion) are first-line therapies for psoriasis and axial spondyloarthritis, inhibiting IL-23/IL-17 axis activation and osteoclastogenesis.

Our Anti-TNFA Neutralizing Antibody Products

Neutralizing antibodies targeting TNFA disrupt its interaction with TNFR1/R2, effectively dampening inflammatory cascades. Creative Biolabs' TNFA specific antibodies are rigorously validated in ELISA, surface plasmon resonance (SPR), and cell-based neutralization assays, ensuring batch-to-batch consistency for drug discovery and mechanistic studies.

-Epitope Specificity: Antibodies binding the RBD or trimerization interface prevent receptor engagement.

-High Affinity: Sub-nanomolar K_D values ensure potent neutralization even at low TNFA concentrations.

-Cross-Reactivity: Validated against human and preclinical models (e.g., murine TNFA) for translational relevance.

Creative Biolabs' TNFA specific neutra™ antibody products offer unmatched specificity and reproducibility for TNFA-focused research and therapeutic development. Engineered to accelerate lead candidate identification and validation, these antibodies are compatible with in vitro assays, in vivo models, and high-content screening platforms. Contact our team to discuss your project requirements and request customized solutions.

REFERENCE

1. Rolski, Filip, and Przemysław Błyszczuk. "Complexity of TNF-α signaling in heart disease." Journal of clinical medicine 9.10 (2020): 3267. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/jcm9103267